|Other Accession||Q99P68, Q99P67, Q9BG79|
|Other Names||Sclerostin, SOST|
|Target/Specificity||The synthetic peptide sequence is selected from aa 27-42 of HUMAN SOST|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.|
|Cellular Location||Secreted, extracellular space, extracellular matrix|
|Tissue Location||Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteoblasts differentiated for 21 days. Detected in the subendothelial layer of the aortic intima (at protein level)|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Semenov,M.V., J. Biol. Chem. 281 (50), 38276-38284 (2006)
Ellies,D.L., J. Bone Miner. Res. 21 (11), 1738-1749 (2006)
Balemans,W., J Musculoskelet Neuronal Interact 6 (4), 355-356 (2006)
Gardner,J.C., J. Clin. Endocrinol. Metab. 90 (12), 6392-6395 (2005)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.